Gemin X Biotechnologies Inc. Phase 1 Data Show Clinical Activity Of GX15-070 In Myelodysplastic Syndromes

MONTREAL--(BUSINESS WIRE)--Gemin X Biotechnologies Inc. announced today results from a Phase 1 clinical trial evaluating GX15-070 administered as a single agent via 24-hour continuous infusion every two weeks in patients with myeloid malignancies and chronic lymphocytic leukemia (CLL). The data indicate that prolonged infusion of GX15-070 induced clinical and biological activity with minimal toxicities. GX15-070 is currently being evaluated in Phase 2 trials as a 24-hour infusion every two weeks in the treatment of Hodgkin's lymphoma and myelofibrosis with myeloid metaplasia.